Except for an NF1-deletion (del17q11) revealed by cytogenetic analysis, no AML-specific genetic abnormalities according to the ELN2017 classification3 were found in the BM at diagnosis, classifying the patient’s AML as intermediate-risk. Here, NF1 is linked to acute myeloid leukemia.